Skip to main content
. 2021 Dec 17;35(1):163–186. doi: 10.1007/s10334-021-00985-2

Table 1.

Inclusion and exclusion criteria

Inclusion criteria Exclusion criteria

● Human patients of all ages and sexes

● Longitudinal data before and after treatment OR cross-sectional design with an appropriate control group or a different treatment arm that allows evaluating the treatment effects after treatment

● Present or past neoplasia anywhere in the body

● Local or systemic treatment by RTx, CTx, or hormone therapy

● Advanced quantitative computed tomography, MRI (i.e. ASL, CEST, DCE, DSC, DKI, IVIM, mcDESPOT, MRS, MRSI, MWI, NODDI, qMT, QSM, relaxometry, VERDICT), PET/SPECT (DOPA, FDG, TRODAT, HMPAO, TSPO, 15O-H2O) imaging in the brain

● Dedicated description of imaging findings in NABT as a reaction to cancer treatment

● Not an original research article (e.g. review, conference proceedings, case study, protocol)

● Preclinical research

● Animal research

● Language other than English

● Study containing results only from structural MRI (e.g. DWI, DTI, brain volumetry, T1w, T2w, FLAIR, STI, SWI) or functional MRI

● Findings are reported in normal tissue only in close vicinity of the tumor

Publications that fulfill all inclusion criteria and neither exclusion criteria were considered. Publications containing additional results to advanced imaging of normal tissue—e.g. extra structural imaging, tumor imaging—were considered